MedPath

Continuous Erector Spinae Block Versus Continuous Edge of Laminar Block on The Quality of Analgesia and Diaphragmatic Excursion in Patients With Multiple Rib Fractures

Not Applicable
Recruiting
Conditions
Erector Spinae Block
Edge of Laminar Block
Analgesia
Diaphragmatic Excursion
Multiple Rib Fractures
Registration Number
NCT07069101
Lead Sponsor
Tanta University
Brief Summary

This prospective randomized clinical trial aims to compare the effect of continuous erector spinae plane block versus continuous edge of laminar block on the quality of analgesia and diaphragmatic excursion in patients with unilateral traumatic multiple rib fractures.

Detailed Description

Rib fractures occur in up to 12% of all trauma patients, most commonly due to blunt thoracic trauma, and pose a significant health care burden with their associated morbidity and mortality.

The erector spinae plane block (ESB) is a myofascial plane technique in which a needle is inserted under ultrasound guidance deep to the erector spinae muscle group, allowing an infusion of local anesthetic to diffuse to both the dorsal and ventral rami of the spinal nerves, thereby supplying the rib cage. This technique can be used as a single-shot method or to facilitate the placement of a catheter, allowing for continuous infusion and/or intermittent bolus to provide long-lasting analgesia.

The edge of laminar block (ELB) is a novel technique in which local anesthetics are injected at the lateral edge of the lamina. It has been proven to provide sensory analgesia during rib fractures.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Aged between 21 and 65 years.
  • Both sexes.
  • With unilateral traumatic multiple fracture ribs (≥ 3), admitted to the surgical intensive care unit within the first day of trauma.
Exclusion Criteria
  • Patients' rejection.
  • Body mass index ≥ 35 (kg/m2).
  • Bleeding and Coagulation disorders.
  • Known hypersensitivity to the study drugs.
  • Vertebral deformity.
  • Respiratory, cardiac, renal or hepatic dysfunction.
  • Patients with major trauma involving extra-thoracic structures (e.g., head, spine, pelvis, and abdominal visceral injuries).
  • Mental or cognitive dysfunction,
  • History of chronic analgesic or drug abuse.
  • Local infection at the site of the block.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Total morphine consumption4 days postoperatively

If the Numeric Rating Scale (NRS) is 4 or more IV morphine 3mg will be given.

Secondary Outcome Measures
NameTimeMethod
Degree of pain4 days postoperatively

The degree of pain will be assessed using the Numeric Rating Scale (NRS) at rest and on coughing will be assessed before the block, at 60 minutes after the block, and then every 8 hours for 4 days.

Diaphragmatic excursion4 days postoperatively

Diaphragmatic excursion will be assessed before the block, at 60 minutes after the block, and then every 8 hours for 4 days.

Incidence of adverse events4 days postoperatively

Incidence of adverse events such as hematoma, local anesthetic systemic toxicity, respiratory complications, pneumothorax, nausea, and vomiting.

Forced vital capacity4 days postoperatively

Forced vital capacity (FVC) will be assessed before the block, at 60 minutes after block, and then every 8 hours for 4 days.

Forced expiratory volume 14 days postoperatively

Forced expiratory volume 1 (FEV1) will be assessed before the block, at 60 minutes after block, and then every 8 hours for 4 days.

Forced expiratory volume 1 (FEV1)/Forced vital capacity (FVC)4 days postoperatively

Forced expiratory volume 1 (FEV1)/Forced vital capacity (FVC) will be assessed before the block, at 60 minutes after block, and then every 8 hours for 4 days.

Trial Locations

Locations (1)

Tanta University

🇪🇬

Tanta, El-Gharbia, Egypt

Tanta University
🇪🇬Tanta, El-Gharbia, Egypt
Heba A Muhammed, Master
Contact
00201032901343
heba.abdelhamid@med.tanta.edu.eg
Mohammed M Abu El Yazed, MD
Sub Investigator
Shaimaa F Abdelkader, MD
Sub Investigator
Mona B Fayad, MD
Sub Investigator
Saad A Mohammed, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.